HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulation/Legislation (Wellness)

Set Alert for Regulation {Wellness}

Regulation

Set Alert for Regulation {Wellness}

Latest From Wellness & Regulation

US FDA Implementing Hybrid Work Policy In January

Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.

FDA Coronavirus COVID-19

Europe's Botanicals Deadlock ‘Unlawful,’ Claims Industry Lawyer

The European Commission’s obvious passivity” with regards to the long-standing botanical health claims deadlock is illegal and violates the provisions of the EU Health Claims Regulation,” argues the German Pharmaceutical Industry Association, on the basis of a legal opinion provided by former constitutional judge Udo Di Fabio.

Europe Germany

‘General Benefit’ Insufficient For EU Food For Special Medical Purposes Classification

In a case that could have far-reaching implications for the region's food supplement manufacturers, the European Court of Justice has ruled that the definition of foods for special medical purposes should be restricted to use in addressing a specific nutrient deficiency related to an illness, as defined by EU law.

Europe Germany
See All

Latest From Wellness & Legislation

Europe's Botanicals Deadlock ‘Unlawful,’ Claims Industry Lawyer

The European Commission’s obvious passivity” with regards to the long-standing botanical health claims deadlock is illegal and violates the provisions of the EU Health Claims Regulation,” argues the German Pharmaceutical Industry Association, on the basis of a legal opinion provided by former constitutional judge Udo Di Fabio.

Europe Germany

Still No Appetite At US FDA For CBD In Food

Three years after similar warnings to make same impression, FDA warns five firms about using in food or beverage products CBD, the cannabinoid most commonly found in US, and delta-8 THC, a subject of ongoing discussion over whether it qualifies as hemp. One firm also warned about CBD in sunscreen.

Cannabidiol CBD FDA

Study Finds Data Scarce Where US FDA Wants To Gauge Hemp Safety – Reproductive Toxicity

First systematic mapping study of safety concerns for consumer use of cannabidiol identifies knowledge gaps for reproductive and developmental toxicity. No traditional, guideline-compliant developmental and reproductive toxicity study was available in the public domain through December 2020.

Cannabidiol CBD FDA
See All
UsernamePublicRestriction

Register